What is the recommended management for developmental dysplasia of the hip in a 3-month-old infant?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Management of Developmental Dysplasia of the Hip in a 3-Month-Old Infant

For a 3-month-old infant with suspected or confirmed DDH, obtain hip ultrasound for diagnosis and initiate Pavlik harness treatment if hip instability or dysplasia is confirmed, with serial ultrasound monitoring throughout treatment. 1, 2

Diagnostic Approach at 3 Months

At 3 months of age, ultrasound is the imaging modality of choice for evaluating DDH 2. The ACR Appropriateness Criteria clearly state that ultrasound is "usually appropriate" for initial imaging of children between 4 weeks to 4 months of age with concern for DDH 2. Radiography is not yet optimal at this age because the femoral head ossific nucleus typically hasn't appeared (appears between 1.5-8 months, often delayed in dysplastic hips) 2.

Physical Examination Findings to Assess:

  • Ortolani and Barlow maneuvers (most reliable up to 3 months) 3
  • Limited hip abduction (becomes increasingly important after 8 weeks of age) 4
  • Asymmetric skin folds and limb shortening (less specific) 2

Important caveat: By 8-12 weeks, capsule laxity decreases and Ortolani/Barlow may become negative even with persistent dysplasia, making limited abduction the key finding 2.

Treatment Protocol

First-Line Treatment: Pavlik Harness

If ultrasound confirms hip instability or dysplasia, initiate Pavlik harness treatment immediately 1, 2. The AAOS guidelines demonstrate successful reduction with Pavlik harness even at 13 weeks of age 1. The harness has an overall success rate of 67-83%, though efficacy is highest when applied before 6 weeks of age 2.

Alternative bracing: Limited evidence supports the von Rosen splint over Pavlik, Craig, or Frejka splints for initial treatment 1.

Monitoring During Treatment

Use serial ultrasound examinations to:

  • Confirm concentric hip reduction 2
  • Assess treatment response 2
  • Identify signs of treatment failure 2

Predictors of Pavlik harness failure include:

  • Low post-reduction alpha angle
  • Less than 20% femoral head coverage 2

The AAOS guidelines recommend "serial physical examinations and periodic imaging assessments throughout treatment duration" 1.

Do not use radiography for monitoring during harness treatment at this age—it's suboptimal due to delayed ossific nucleus appearance and poor positioning within the harness 2. Radiographs are obtained at or near conclusion of treatment to document bony acetabular development 2.

Management Algorithm Based on Severity

If Hip is Unstable (Positive Ortolani/Barlow):

  1. Obtain ultrasound confirmation
  2. Initiate Pavlik harness immediately
  3. Serial ultrasound monitoring (timing per orthopedist)
  4. Continue until hip stable and acetabular development normalizes

If Hip is Stable but Ultrasound Shows Abnormalities:

The AAOS guidelines support observation without bracing for stable hips with ultrasound abnormalities (e.g., alpha angle 45° vs normal 60°) 1. However, this requires close follow-up with repeat imaging.

If Equivocal Examination:

  • Reexamine in 2 weeks 4
  • If still equivocal at 6 weeks, refer to orthopedics 4
  • Consider ultrasound if findings persist 4

Critical Timing Considerations

The 3-month age is within the optimal treatment window. The Pavlik harness can be used up to 6 months of age, but efficacy decreases with age 2. Surgical intervention is reserved for children with severe dysplasia, late presentation, or failed nonoperative management 2.

Common Pitfalls to Avoid

  1. Don't delay imaging: At 3 months, physical examination alone may miss dysplasia as Ortolani/Barlow become less reliable 2
  2. Don't use radiography at this age: Ultrasound is superior for diagnosis and monitoring before 4-6 months 2
  3. Don't undertreate stable hips with significant ultrasound abnormalities: While observation is supported for mild abnormalities, significant dysplasia requires treatment 1
  4. Monitor for avascular necrosis: This is the most significant treatment complication 4

Referral Indications

Immediate orthopedic referral is indicated for:

  • Overtly dislocated or dislocatable hips at diagnosis 4
  • Failed harness treatment
  • Persistent instability beyond 6 weeks of treatment

The goal is to achieve a stable, concentrically reduced hip with normal acetabular development, preventing early-onset hip osteoarthritis in adulthood 3, 4.

References

2
Guideline

acr appropriateness criteria<sup>®</sup> developmental dysplasia of the hip-child.

Journal of the American College of Radiology, 2019

3
Research

Developmental Dysplasia of the Hip.

American family physician, 2025

Related Questions

What are the indications, methods, and timing for screening developmental dysplasia of the hip in newborns and infants?
What is developmental dysplasia of the hip (DDH)?
In a 9‑month‑old female infant with an asymmetric medial lower left leg skin fold that does not encircle the leg, normal developmental milestones, and no history of developmental dysplasia of the hip, what is the appropriate management?
If a fetus converts from breech to vertex presentation at 35 weeks gestation, is a hip ultrasound still required to screen for developmental dysplasia of the hip?
How is the Ortolani maneuver performed in a newborn or infant up to 6 months with suspected developmental dysplasia of the hip, and what finding indicates a positive result?
Can a child who wears glasses and has uncorrected visual acuity of 20/100 be cleared for sports if they use corrective lenses and have no other ocular or systemic concerns?
What is the significance and recommended management for an LDL cholesterol level of 117 mg/dL in an 11‑year‑old child?
Should lamotrigine be taken in the morning or evening, and can it be co-administered with venlafaxine in the evening?
What epinephrine auto‑injector (EpiPen) dose should be administered based on a patient's weight?
In a 36-year-old patient in rehab after alcohol and fentanyl detoxification, with chronic low back pain and depression treated with duloxetine 90 mg, who is now showing signs of delayed oxycodone withdrawal (red eyes without discharge, myalgias, yawning), should Suboxone (buprenorphine/naloxone) be started, and how should the induction be performed?
In an 88-year-old patient with an eGFR of 28 mL/min/1.73 m² who is taking tamsulosin 0.4 mg daily, is a dose adjustment required?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.